Perspectives in melanoma: meeting report from the “Melanoma Bridge” (December 5th–7th, 2019, Naples, Italy)

Perspectives in melanoma: meeting report from the “Melanoma Bridge” (December 5th–7th, 2019, Naples, Italy)

Abstract The melanoma treatment landscape changed in 2011 with the approval of the first anti-cytotoxic T-lymphocyte-associated protein (CTLA)-4 checkpoint inhibitor and of the first BRAF-targeted monoclonal antibody, both of which significantly improved overall survival (OS). Since then, improved u...

Full beskrivning

Bibliografiska uppgifter
Huvudupphovsmän: Paolo A. Ascierto, Igor Puzanov, Sanjiv S. Agarwala, Christian Blank, Richard D. Carvajal, Sandra Demaria, Reinhard Dummer, Marc Ernstoff, Soldano Ferrone, Bernard A. Fox, Thomas F. Gajewski, Claus Garbe, Patrick Hwu, Roger S. Lo, Georgina V. Long, Jason J. Luke, Iman Osman, Michael A. Postow, Ryan J. Sullivan, Janis M. Taube, Giorgio Trinchieri, Hassane M. Zarour, Corrado Caracò, Magdalena Thurin
Materialtyp: Artikel
Språk:English
Publicerad: BMC 2020-09-01
Serie:Journal of Translational Medicine
Ämnen:
Melanoma
Immunotherapy
Anti-PD-1
Anti-CTLA-4
Target therapy
Biomarkers
Länkar:http://link.springer.com/article/10.1186/s12967-020-02482-x

Internet

http://link.springer.com/article/10.1186/s12967-020-02482-x

Liknande verk